Distinct Antibody Responses to Endemic Coronaviruses Pre- and Post-SARS-CoV-2 Infection in Kenyan Infants and Mothers

Caitlin I. Stoddard, Kevin Sung, Ednah Ojee, Judith Adhiambo, Emily R. Begnel, Jennifer A. Slyker, Soren Gantt, F. A. Matsen, John Kinuthia, Dalton Wamalwa, Julie Overbaugh, Dara A. Lehman

TL;DR

This study investigated how pre-existing antibodies to common human coronaviruses (eHCoVs) influence SARS-CoV-2 infection in Kenyan mothers and infants. They found that while SARS-CoV-2 infection boosted antibody responses to some eHCoVs in mothers, this effect was absent in infants, suggesting that prior immune memory plays a role in this boosting phenomenon.

What Problem Does This Paper Address?

The COVID-19 pandemic has highlighted the complex interplay between SARS-CoV-2 and pre-existing immunity to other coronaviruses, known as endemic human coronaviruses (eHCoVs). These eHCoVs, responsible for common colds, share structural similarities with SARS-CoV-2, leading to the hypothesis that antibodies developed against eHCoVs might offer some cross-protection or influence the immune response to SARS-CoV-2. However, much of this research has focused on adults, leaving a significant knowledge gap regarding how these interactions manifest in infants, who have unique immunological profiles and are born with maternally derived antibodies. This paper aims to address this gap by examining antibody responses to eHCoVs and SARS-CoV-2 in a cohort of mothers and their infants in Kenya.

Methods

The researchers utilized a longitudinal study design, collecting plasma samples from mothers and infants over time. They employed a multiplexed chemiluminescent antibody binding immunoassay to measure IgG antibody titers against the spike proteins of four eHCoVs (HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63) and SARS-CoV-1. Samples were collected at different time points: pre-pandemic, during the period just before SARS-CoV-2 seroconversion (last negative), and after SARS-CoV-2 seroconversion (first seropositive). Statistical analyses, including Wilcoxon rank-sum and signed-rank tests with Holm-Bonferroni correction for multiple hypothesis testing, were used to compare antibody titers between different groups and time points.

Datasets

The study utilized plasma samples from the Linda Kizazi cohort in Nairobi, Kenya. These samples were collected between April 2019 and December 2020. The participants were categorized based on their SARS-CoV-2 serostatus (seroconverters vs. never-seropositive) and the timing of sample collection relative to SARS-CoV-2 infection.

Key Insights and Ideas

  • Maternal antibody transfer is evident: Infants, especially at younger ages, show similar antibody levels to their mothers for eHCoVs, reflecting the passive transfer of antibodies from mother to child.
  • Waning infant immunity: As infants age, their eHCoV antibody levels decrease, likely due to the natural waning of maternally derived antibodies and limited exposure opportunities.
  • SARS-CoV-2 boosts betacoronavirus antibodies in mothers: Following SARS-CoV-2 infection, mothers showed increased antibody titers against betacoronaviruses like HCoV-OC43 and HCoV-HKU1, suggesting a boosting of pre-existing cross-reactive memory responses.
  • Infants lack this boosting effect: Crucially, infants did not exhibit a similar increase in eHCoV antibody levels after SARS-CoV-2 seroconversion, indicating that the boosting phenomenon observed in mothers might depend on established immune memory, which is less developed in infants.
  • SARS-CoV-1 cross-reactivity is universal: Both mothers and infants showed increased antibody responses to SARS-CoV-1 after SARS-CoV-2 infection, supporting the idea that SARS-CoV-2 infection can elicit cross-reactive responses to closely related coronaviruses, even in individuals unlikely to have been previously infected with SARS-CoV-1.
  • Pre-existing eHCoV immunity isn't a strong predictor of SARS-CoV-2 infection: The study found no consistent association between pre-existing eHCoV antibody levels and the risk of SARS-CoV-2 seroconversion in either mothers or infants, suggesting that these antibodies don't strongly dictate susceptibility.

Key Results

  • In mothers, antibody titers against HCoV-OC43 and HCoV-HKU1 significantly increased after SARS-CoV-2 seroconversion.
  • Antibody titers against SARS-CoV-1 also significantly increased in both mothers and infants after SARS-CoV-2 seroconversion.
  • No significant increase in eHCoV antibody levels was observed in infants following SARS-CoV-2 seroconversion.
  • A modest, though not statistically significant after correction, association was found between lower HCoV-229E antibody levels and SARS-CoV-2 seronegativity in infants.

Limitations and Future Work

The authors acknowledge that their study is limited by sample size and potential heterogeneity in SARS-CoV-2 exposure risk within the study population. They suggest that further studies with larger cohorts are needed to definitively evaluate the association between pre-existing eHCoV antibody titers and SARS-CoV-2 seroconversion. Future research could also delve deeper into the specific mechanisms behind the differential antibody responses observed between mothers and infants and explore the functional implications of these cross-reactive antibodies in newborns and young infants.

Summary updated

Abstract

Pre-existing antibodies that bind endemic human coronaviruses (eHCoVs) can cross-react with SARS-CoV-2, which is the betacoronavirus that causes COVID-19, but whether these responses influence SARS-CoV-2 infection is still under investigation and is particularly understudied in infants. In this study, we measured eHCoV and SARS-CoV-1 IgG antibody titers before and after SARS-CoV-2 seroconversion in a cohort of Kenyan women and their infants. Pre-existing eHCoV antibody binding titers were not consistently associated with SARS-CoV-2 seroconversion in infants or mothers; however, we observed a very modest association between pre-existing HCoV-229E antibody levels and a lack of SARS-CoV-2 seroconversion in the infants. After seroconversion to SARS-CoV-2, antibody binding titers to the endemic betacoronaviruses HCoV-OC43 and HCoV-HKU1, and the highly pathogenic betacoronavirus SARS-CoV-1, but not the endemic alphacoronaviruses HCoV-229E and HCoV-NL63, increased in the mothers. However, eHCoV antibody levels did not increase following SARS-CoV-2 seroconversion in the infants, suggesting the increase seen in the mothers was not simply due to cross-reactivity to naively generated SARS-CoV-2 antibodies. In contrast, the levels of antibodies that could bind SARS-CoV-1 increased after SARS-CoV-2 seroconversion in both the mothers and infants, both of whom were unlikely to have had a prior SARS-CoV-1 infection, supporting prior findings that SARS-CoV-2 responses cross-react with SARS-CoV-1. In summary, we found evidence of increased eHCoV antibody levels following SARS-CoV-2 seroconversion in the mothers but not the infants, suggesting eHCoV responses can be boosted by SARS-CoV-2 infection when a prior memory response has been established, and that pre-existing cross-reactive antibodies are not strongly associated with SARS-CoV-2 infection risk in mothers or infants.
BibTeX
@inproceedings{stoddard2022distinct,
  author = {Caitlin I. Stoddard and Kevin Sung and Ednah Ojee and Judith Adhiambo and Emily R. Begnel and Jennifer A. Slyker and Soren Gantt and F. A. Matsen and John Kinuthia and Dalton Wamalwa and Julie Overbaugh and Dara A. Lehman},
  title = {{Distinct Antibody Responses to Endemic Coronaviruses Pre- and Post-SARS-CoV-2 Infection in Kenyan Infants and Mothers}},
  booktitle = {Viruses},
  year = {2022},
  doi = {10.3390/v14071517},
}

Loading related content...

Figure